Front Matter

Main Article Content

Urologic Cancers
Neil Barber, MBBS, FRCS (Editor)
Ahmed Ali, MBCHB, MSC, FRCS (Editor)

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

Section
Prelim
Author Biographies

Neil Barber, MBBS, FRCS (Editor), Frimley Park Hospital, Frimley Health NHS Foundation Trust, Camberley, UK

Neil Barber, MBBS, FRCSNeil Barber, MBBS, FRCS is a Consultant Urological Surgeon at Frimley Park Hospital, Clinical Lead for Urology at Frimley Health NHS Foundation Trust, and Director of the Frimley Renal Cancer Centre. Dr. Barber Leads the tertiary referral center for renal cancer surgery at Frimley Health NHS Foundation Trust, UK. He also created a very successful Royal College of Surgeons of England certified fellowship program to train urologists on all renal surgeries including robotic and minimally invasive renal surgery. Dr. Barber provides the full breadth of Urological care, including issues ranging from prostate cancer, urinary tract infections, prostatitis, and penoscrotal conditions. Dr. Barber is recognized as a Key Opinion Leader and clinical advisor both to industry and to NICE.

Ahmed Ali, MBCHB, MSC, FRCS (Editor), Frimley Park Hospital, Frimley Health NHS Foundation Trust, Camberley, UK

Ahmed Ali, MBChB, MSc, FRCSAhmed Ali, MBChB, MSc, FRCS is a Consultant Urological Surgeon at Frimley Health Foundation NHS Trust, UK. Dr. Ali leads the bladder cancer services and is a core member of the Urology Department at Frimley Park Hospital. After receiving Master’s degree in Urology from University College of London in 2013, Dr. Ali continued to gain his expertise in managing urologic oncology while undertaking a fellowship post at Addenbrookes hospital in Cambridge. Recently, Dr. Ali introduced multiple new treatments for bladder cancer at Frimley Health such as En-bloc resection of a bladder tumor, Transurethral laser ablation/resection of bladder tumor, and hyperthermic mitomycin treatment for BCG failure patients. Dr. Ali is currently involved in NIHR-funded trial to investigate the role of novel markers in overactive bladder syndrome.